Lee Pitcher MP: written questions
4 Jul 2025–3 Jul 2026
How these years work
Our reporting years run from 4 July to 3 July, starting with the 2024 general election. They are not official parliamentary sessions. Office costs keep IPSA’s April–March financial years. Records may cover only part of a year; a missing record does not mean no work was done.
Written questions: dates and coverage
- Source checked
- 21 Nov 2026
- Last successful import
- 21 Nov 2026
- Records dated through
- 20 Nov 2026
- Selected period
- Reporting year 2: 4 Jul 2025 to 3 Jul 2026
- Completeness
- Published snapshot: 25,747 records in the source window 23 Aug 2026 to 21 Nov 2026. The published snapshot covers its stated source window. Answers and corrections can appear later; no indexed answer does not prove that none exists.
Understand written questions, dates and answers.
Read what this MP said, asked and contributed in Parliament.
39 published records · newest first.
Written questions
Sodium Valproate and Surgical Mesh Implants: CompensationDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15255More
Question: To ask the Secretary of State for Health and Social Care, if he will ensure that the Government provides, by 16 July 2026, the information requested by the Patient Safety Commissioner on (a) action taken in response to the Hughes Report, (b) outstanding s
Answer: The Patient Safety Commissioner wrote to the Prime Minister on 16 June, requesting information regarding internal and cross-Government discussions in relation to the Hughes Report, actions that have been taken beyond the Department, and the future plans r...
Answered 6 Jul 2026
Original Parliament recordMigraines: EmploymentDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15253More
Question: To ask the Secretary of State for Health and Social Care, whether he plans to collect or publish data on the number of people whose work capability is affected by migraine or related headache disorders.
Answer: The Office for National Statistics collects information on health conditions through the Labour Force Survey (LFS), which is based on interviews with people resident in households in the United Kingdom. The LFS covers this in two relevant ways. It asks re...
Answered 15 Jul 2026
Original Parliament recordMigraines: EmploymentDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15252More
Question: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage employers to provide reasonable workplace support for employees affected by migraine.
Answer: The Government is committed to working collaboratively to support disabled people and people with health conditions, including people affected by migraine. The Department of Health and Social Care and the Department for Work and Pensions’ Joint Work and H...
Answered 10 Jul 2026
Original Parliament recordMigraines: EmploymentDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15251More
Question: To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the Secretary of State for Health and Social Care on cross-government support for people whose ability to work is affected by migraine.
Answer: The Government is committed to working collaboratively to support disabled people and people with health conditions, including people affected by migraine. The Department of Health and Social Care and the Department for Work and Pensions’ Joint Work and H...
Answered 10 Jul 2026
Original Parliament recordMigraines: EmploymentDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15250More
Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the impact of migraine on levels of employment, absenteeism and economic inactivity in sufferers.
Answer: No assessment has been made of the potential impact of migraine on employment and economic inactivity. This information isn’t available as the Labour Force Survey (LFS), the primary source for data on labour market participation and economic inactivity, o...
Answered 16 Jul 2026
Original Parliament recordMigraines: Health ServicesDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15249More
Question: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that patients can access the most effective innovations for migraine.
Answer: The National Institute for Health and Care Excellence (NICE) has recommended several new medicines as options for the treatment of migraine. The National Health Service in England is legally required to fund medicines recommended in a NICE appraisal, usua...
Answered 8 Jul 2026
Original Parliament recordMigraines: Health ServicesDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15248More
Question: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve outcomes for people living with migraine.
Answer: The Government recognises the significant impact that migraine can have on individuals’ quality of life and is committed to improving care and outcomes for people living with this condition.NHS England is supporting improvements in migraine care through n...
Answered 10 Jul 2026
Original Parliament recordDisability: ChildrenDepartment of Health and Social CareTabled 30 Jun 2026AnsweredUIN 14747More
Question: To ask the Secretary of State for Health and Social Care, what guidance his Department provides to NHS and local authority professionals on responsibility for commissioning specialist night-time safety equipment for children with complex developmental dis
Answer: The Children and Families Act 2014 requires that education, health, and social care services must work together to meet the needs of children and young people with special educational needs and disabilities (SEND). Integrated care boards (ICBs) are respon...
Answered 17 Jul 2026
Original Parliament recordBreasts: Plastic SurgeryDepartment of Health and Social CareTabled 16 Jun 2026AnsweredUIN 10443More
Question: To ask the Secretary of State for Health and Social Care, whether his Department plans to commission updated research into the long-term health effects of Poly Implant Prothèse breast implants on women.
Answer: The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is not currently funding any specific research into long-term health effects of Poly Implant Prothèse breast (PIP) implants but welcomes fundi...
Answered 30 Jun 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9219More
Question: To ask the Secretary of State for Health and Social Care, what information his Department holds on (a) the likelihood of patients who develop one dopamine agonist-associated impulse control disorder developing additional impulse control disorders and (b)
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9217More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome alone, compared with patients with restless legs syndrome and attention deficit hyperactivity disorder, auti
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9216More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome treated with dopamine agonists who have co-existing neurodevelopmental or psychiatric diagnoses, including a
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9215More
Question: To ask the Secretary of State for Health and Social Care, what assessment the Department has made of risk factors for dopamine agonist-induced impulse control disorders, including age, renal impairment, duration of exposure, cumulative dose, polypharmacy,
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9214More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on the average age at (a) initiation of dopamine agonist therapy, (b) first report or diagnosis of an impulse control disorder while taking a dopamine agonist and (c)
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9213More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the average length of time patients remain on dopamine agonists or partial dopamine agonists for each licensed indication, (b) the proportion of patients who r
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9212More
Question: To ask the Secretary of State for Health and Social Care, what information national pharmacovigilance systems and clinical datasets provide on the range and relative frequency of withdrawal symptoms associated with dopamine agonist discontinuation, includ
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9211More
Question: To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the average time from initiating a dopamine agonist, or increasing its dose, to (a) the onset or first report of impulse control disorder symptoms and (
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9210More
Question: To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the number and proportion of patients who develop impulse control disorders while taking dopamine agonists and subsequently (a) continue dopamine agonis
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9209More
Question: To ask the Secretary of State for Health and Social Care, what data national bodies hold on (a) the number and proportion of people prescribed dopamine agonists who self-report impulse control disorders and (b) the number and proportion whose impulse cont
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9208More
Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the use of artificial intelligence and digital tools within the NHS and the Medicines and Healthcare products Regulatory Agency to (a) detect potential do
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9207More
Question: To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the effectiveness of how dopamine agonist-related impulse control disorders and augmentation are taught and assessed in undergraduate medical educat
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9206More
Question: To ask the Secretary of State for Health and Social Care, whether his Department holds audit or research data on differences between neurology or movement disorder specialists and general practitioners in (a) warning patients and families about dopamine a
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9205More
Question: To ask the Secretary of State for Health and Social Care, what guidance is issued to clinicians on discussing in advance with patients, and where appropriate their families, how treatment should be managed if severe impulse control disorders develop while
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9204More
Question: To ask the Secretary of State for Health and Social Care, what assessment the Department has made of the levels of (a) sexually transmitted infections acquired in the context of dopamine agonist-induced hypersexuality and (b) unplanned pregnancies among w
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament recordDrugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9203More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the number and proportion of dopamine agonist-treated patients who report binge eating or marked weight gain, (b) weight and metabolic monitoring practices whe
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Explore activity by topic or department
Written questions by answering department
4 Jul 2025–3 Jul 2026. One record per UIN and tabled date; the named department is not a measure of answer quality.
View as listWhat this shows and doesn't show
Published records only — not a full account of an MP’s work. How we work →